

**Texas Diabetes Council's
Health Care Professionals Advisory Committee
Approved Meeting Minutes
November 7, 2002**

Charles Reasner, MD, Chair

Attendees:

Maria C. Alen, MD
Robin Atwood, PhD
M. M. Bakdash, MD, FACE
Pete Baker
Karen Bauer-Smith, RN
Belinda Bazan-Lara MA, RD/LD
Gene Bell, RN, CFNP, CDE
Gregory Fuest
Mary Ann Galley, PharmD, RPh
Robin Gilchrist
Carolyn M. Grubb, CDE, RD/LD
Judy Haley
Hanks Hanna
Sylvia Harris
Carlos Harvey
Magaret Hedrick, RN, CDE
Jeffrey A. Jackson, MD, CDE
Charles Lucas

John A. Menchaca, MD
Richard Nelson, MD
Margaret Pacillas, RN, CDE
Shay Reichert
Linda Greenhouse Robinson
Robin Selsor
Lance Sloan, MD
Craig W. Spellman, PhD, DO
Curtis Triplitt, PharmD, CDE
Chris G. Vales

TDH Program Staff

Pat Black
Maria I. Gomez
Philip Huang, MD, MPH
Jan M. Ozias, RN, PhD

1. Call to Order

Dr. Reasner called the meeting to order at 10:10 A.M in Moreton 653, TDH.

2. Designation of Recorder

Texas Diabetes Staff to record the meeting minutes.

3. Meeting Minutes Approval

A motion was made by Margaret Pacillas and seconded by Dr. Nelson to approve the meeting minutes from August 15, 2002. Approved unanimously.

4. Presentation

Dr. Reasner introduced Ralph A. DeFronzo, MD who presented on the role of Orlistat (Xenical) in treatment of obese diabetic and non-diabetic patients. He reviewed clinical trials concerning the efficacy of orlistat in promoting weight loss in obese individuals, in reducing HbA1c levels in obese persons with type 2 diabetes, in limiting the progression of impaired glucose tolerance onto type 2 diabetes, and in correcting components of the Metabolic Syndrome.

Weight loss is the best “medicine” for the obese diabetic patient.

5. Outcomes and Standards Compliance advisory subcommittee

Dr. Menchaca reviewed the subcommittee’s meeting and progress made on data collection, e.g., the HEDIS measures can be used to depict geographical (health plan service area) differences in the six diabetes care indicators.

6. Standards of Care Subcommittee Report

Standards of Care Advisory Subcommittee: Jeffrey Jackson, MD reported three recommendations from the Standards of Care subcommittee to amend three current documents, noting that drug agents will be added subject to FDA approvals. On voice vote, these were approved as submitted to the HCPC:

1. A new Antiplatelet therapy paper (as prelude to a Macrovascular Algorithm) with 2002 references.
2. Amend the Lipid treatment algorithm. Rationale: more specific, recognize FDA-approved products; other algorithms have been created to address issues such as hypertension control; the algorithm addresses strategies other than medications, e.g., exercise, nutrition.
3. Lance Sloan, MD proposed the addition of a disclaimer to all algorithms in print and on website. The disclaimer will be reviewed by TDH legal counsel. Rationale: Algorithms are a treatment option; this would limit perceived liability. It should be sufficient if added to website before one can access an algorithm.
4. The Subcommittee is working on insulin algorithms for type 1 and 2, type 2 diabetes prevention and obesity algorithm. They will examine evidence for including Orlistat in an obesity algorithm.

7. Materials Dissemination Report

Ms. Villagomez has conveyed that the group is updating resource materials.

8. Discussion

Council member Lenore Katz inquired about the need for public education material on “prediabetes”. Group discussed metabolic syndrome, insulin resistance syndrome, which may or may not include Impaired Glucose Tolerance. It was recommended that the Council be proactive on the topic and Dr. DeFronzo agreed to serve a consultant.

9. Adjournment

Dr. Reasner adjourned the meeting at 11:40 A.M.